IFNA1, interferon alpha 1, 3439

N. diseases: 662; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Peginterferon alpha-2a (Peg-IFN α-2a) is a recommended international guideline for treatment of CHB children, which is limited to children aged > 3 years. 31487005 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE (Pegylated) Interferon ([Peg]IFN) therapy leads to response in a minority of chronic hepatitis B (CHB) patients. 30715261 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 AlteredExpression disease BEFREE Through PCR array, we found higher baseline level of IFN-induced transmembrane protein 2 (IFITM2) mRNA and lower baseline level of IFNα mRNA in peripheral blood mononuclear cells (PBMCs) of CHB patients with suboptimal response to IFNα treatment. 30723923 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Peg-IFN-α monotherapy is a treatment option recommended by local and international clinical practice guidelines to help more CHB patients achieve a sustained off-treatment virological response, which is particularly appropriate for relatively young patients who demand a finite treatment approach. 31380584 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 GeneticVariation disease BEFREE Our data support that SNP rs7574865 is associated with response to PEG-IFN therapy in Thai patients with CHB, regardless of baseline HBeAg status. 31421662 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 AlteredExpression disease BEFREE Using independent and agnostic bioinformatics approaches, CD45<sup>+</sup>CD11c<sup>+</sup> and CD45<sup>+</sup>CD11c<sup>-</sup> human leukocytes flow sorted from the CHB hearts highly expressed type I IFN response genes inclusive of SIGLEC1. 30518570 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE <b>Conclusion:</b> Peg-IFN combined with TDF may increase the virological response rate, biochemical response rate, and HBsAg loss rate in patients with CHB infection. 31114265 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE The level of NK cells was decreased in hepatitis B-associated liver cirrhosis significantly and had no changes in CHB or hepatocellular carcinoma, while the frequency of NK cells gradually decreased from the baseline to week 24 and then increased since week 24-48 in CHB with IFN-<i>α</i> treatment. 31158068 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Our results indicated that serum TCHO was associated with PEG-IFN-α therapeutic response in HBeAg-positive CHB patients which suggested that serum TCHO could be useful as an auxiliary clinical factor to predict poor efficacy of PEG-IFN-α therapy. 30520414 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE We evaluated whether Thymopentin (TP5) and interferon (IFN-a) had a synergic effect on HBV cccDNA and the effect of TP5 addition therapy on HBsAg clearance in CHB patients. 30860474 2019
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Pre-therapy with ADV or ETV followed by PEG-IFN alfa-2a is not superior to PEG-IFN alfa-2a monotherapy in Taiwanese patients with HBeAg-positive CHB. 29456079 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients. 29790851 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE The aim of this study was to evaluate the relationship between interleukin-21 (IL-21) and interleukin-21 receptor (IL-21R) polymorphisms and the response to peginterferon alfa (PEG-IFN α) therapy in HBeAg-positive chronic hepatitis B (CHB) patients.A total of 143 HBeAg-positive CHB patients treated for 48 weeks with PEG-IFN α and followed up for 24 weeks post-treatment were retrospectively evaluated. 29879024 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Combination with ETV and PEG-IFN could be an option for treatment of CHB patients especially in those with baseline HBsAg levels of less than 3.5 log U/ml. 29438098 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE IFN-λ has recently been tested in clinical trials of chronic hepatitis B virus infection (CHB), with the advantage that side effects may be limited compared with IFN-α, as IFN-λ receptors are found only in epithelial cells. 30097535 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 GeneticVariation disease BEFREE Thirty CHB subjects on long-term treatment with tenofovir (TDF) and HBV suppression were enrolled and randomized 1:2 to either receive Peg-IFN-α-2a add-on therapy or continue TDF alone. 29091327 2018
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE In order to characterize the correlation between Peg-IFN-α antiviral effect and IFN-inducing signaling in CHB patients who switched to Peg-IFN from long time entecavir (ETV) treatment, we investigated the dynamic expression of interferon-stimulated genes (ISGs), including STAT1, MX, and a negative regulatory factor, suppressor of cytokine signaling 3(SOCS3), which negatively regulate IFN JAK-STAT signaling pathway by interacting with STAT1 and STAT2, in peripheral blood and paired liver samples, obtained from 54 CHB patients enrolled in a clinical trial, OSST study. 28988797 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 GeneticVariation disease BEFREE In this study, we aimed to investigate the expression and function of TLR8 in peripheral blood mononuclear cells (PBMCs) of chronic hepatitis B (CHB) patients and its alteration during peg-IFN-α-2a therapy. 28236535 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 GeneticVariation disease BEFREE Our data suggest that SNP rs4646536 in the CYP27B1 gene is a predictive factor of response to PEG-IFN therapy in Thai patients with CHB. 28291736 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE However, only a minority of chronic hepatitis B (CHB) patients generate a sustained response after treatment with recombinant IFNα. 27839836 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE These results indicate the involvement of miR-548j in aberrant production of type I IFN in CHB patients, and provide a potential target for developing anti-HBV therapies. 28342861 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Our data have important implications for the treatment of CHB patients who fail to show an early response to Peg-IFNα-2a monotherapy. 28854883 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 GeneticVariation disease BEFREE Compared to the rs7574865 GT/TT genotype, the GG genotype (a risk factor of CHB and hepatitis B virus-related hepatocellular carcinoma) was significantly associated with a reduced SVR rate in both patients who received IFNα-2b therapy (21.1% versus 37.2%, P = 0.01) and those who received pegylated IFNα-2a therapy (18.0% versus 41.2%, P = 9.74 × 10(-5) ). 26704347 2016
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Even after stimulation by TLR agonists, no change was found in IFN-α production in CHB patients. 27658394 2016
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block
0.100 Biomarker disease BEFREE Data from this study demonstrated for the first time that IP-10 polymorphism is independently associated with treatment response to PEG-IFN in patients with HBeAg-positive CHB. 26376789 2016